Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Aug;25(8):573-589.
doi: 10.1038/s41568-025-00831-w. Epub 2025 Jun 16.

Neuro-immune cross-talk in cancer

Affiliations
Review

Neuro-immune cross-talk in cancer

Moran Amit et al. Nat Rev Cancer. 2025 Aug.

Abstract

The nervous and immune systems have co-evolved to detect and respond to internal and external threats, working together to restore homeostasis after tissue injury or infection. Sharing several receptors and ligands, they engage in direct cross-talk that substantially influences disease development. The emerging field of cancer neuro-immunity focuses on the intricate interactions between the nervous system, immune responses and tumour growth. Additional findings have revealed that nerve fibres infiltrating peripheral tumours can release neuromodulatory factors that shape both immune cell behaviour and tumour progression. Conversely, tumour-infiltrating immune cells can modify the activity of local neurons, including pain-transmitting nociceptive sensory neurons. Beyond sensory fibres, sympathetic signalling can foster immunosuppression by recruiting myeloid-derived suppressor cells and promoting T cell exhaustion. This Review summarizes current evidence on how neuronal signalling regulates peripheral antitumour immune responses within the tumour microenvironment. We describe the complex, reciprocal interactions among neurons, immune cells and malignant cells, highlighting the key parts played by the peripheral nervous system in modulating immunity against cancer. By understanding this neuro-immune axis, novel therapeutic approaches may be uncovered to strengthen antitumour immunity and enhance responses to existing cancer treatments.

PubMed Disclaimer

Conflict of interest statement

Competing interests: The authors declare no competing interests.

References

    1. Pardoll, D. M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12, 252–264 (2012). - PubMed - PMC
    1. Zhao, L., Singh, V., Ricca, A. & Lee, P. Survival benefit of pembrolizumab for patients with pancreatic adenocarcinoma: a case series. J. Med. Cases 13, 240–243 (2022). - PubMed - PMC
    1. Storandt, M. H., Tran, N., Martin, N. & Jatoi, A. Pembrolizumab near the end of life in patients with metastatic pancreatic cancer: a multi-site consecutive series to examine survival and patient treatment burden. Cancer Immunol. Immunother. 72, 2515–2520 (2023). - PubMed - PMC
    1. Emens, L. A. et al. Challenges and opportunities in cancer immunotherapy: a Society for Immunotherapy of Cancer (SITC) strategic vision. J. Immunother. Cancer 12, e009063 (2024). - PubMed - PMC
    1. Young, H. H. On the presence of nerves in tumors and of other structures in them as revealed by a modification of Ehrlich’s method of ‘vital staining’ with methylene blue. J. Exp. Med. 2, 1–12 (1897). - PubMed - PMC

LinkOut - more resources